Viking Therapeutics (NASDAQ:VKTX) reported additional positive data from its phase 1 trial of the oral version of its VK2735, the dual GLP-1/GIP agonist for the treatment of obesity and related ...

SAN AN­TO­NIO — Well be­hind No­vo Nordisk and Eli Lil­ly in the obe­si­ty race, As­traZeneca came to this year’s Obe­si­ty­Week with three as­sets in hand … ...

Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial In return for granting Novo the license to use the platform for the lead GLP-1 program, Ascendis is ...

Companies such as Pfizer, Roche and Viking Therapeutics are also developing oral GLP-1 weight-loss drugs. AstraZeneca said it is focussing on the combination potential of its weight-loss drug ...

While Pfizer isn’t the only pharma giant betting on oral GLP-1s, the company is all in with more than one candidate in the works. And despite two clear leaders in the space — Novo Nordisk and ...

Viking designed VK2735 to target and activate the GLP-1 and GIP receptors ... Viking has reached clinical testing with injectable and oral versions of its drug candidate. These strategies and ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial ... Lian added that the durable effects at 28 days of dosing in the oral Phase 1 study suggested ...

Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million ...

However, retained gastric contents were not a problem in a subset of patients taking GLP-1 drugs who had been ... followed by oral naltrexone and topiramate. “Providers caring for patients ...

I do not know how to put this gently or tastefully, so I will factually describe what happened last night in Milwaukee: A former president of the United States held a rally, during which he used a ...

All drug candidates in the pipeline are based on GLP-1 agonists, and the most advanced is currently being tested in phase 1 clinical trials. Structure Therapeutics is a global biopharmaceutical ...